Navigation Links
AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
Date:8/4/2008

Active second quarter stock repurchase program and positive cash flow from

operations

BOSTON, Aug. 4 /PRNewswire-FirstCall/ -- AMICAS, Inc. (Nasdaq: AMCS), a leader in radiology and medical image and information management solutions, today reported unaudited financial results for the second quarter ended June 30, 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO )

Q2 Financial Highlights

Revenue: Total revenues for the second quarter of 2008 were $13.6 million, compared to $12.5 million for the second quarter of 2007.

Operating Loss: Operating loss for the second quarter of 2008 was $602,000, compared to an operating loss of $1.4 million for the second quarter of 2007.

Net Loss: The Company's net loss for the second quarter of 2008 was $97,000, or $(0.00) per share, compared to net loss of $480,000, or $(0.01) per share, for the second quarter of 2007.

In the second quarter of 2008, both operating loss and net loss included $185,000 of non-cash stock-based compensation expense and $848,000 of depreciation and amortization. In the second quarter of 2007, both operating loss and net loss included $510,000 of non-cash stock-based compensation expense and $740,000 of depreciation and amortization.

Pro-forma EBITDA: Pro-forma EBITDA, a non-GAAP financial measure, was $431,000 in the second quarter of 2008 as compared to a loss of $134,000 in the second quarter of 2007.

"Pro-forma EBITDA," a non-GAAP financial measure, refers to net income, adjusted for amortization, depreciation, interest, taxes, and stock compensation expense. A reconciliation o CONDENSED Consolidated Statements Of Cash Flows

(Unaudited)

(in thousands)

Six Months Ended

June 30,

2008 2007

Operating activities

Net loss $(564) $(334)

Adjustments to reconcile net loss to cash

provided by operating activities:

Depreciation and amortization 552 538

Provisions for (recoveries from) bad debts 110 (341)

Loss on disposal of fixed assets 6 -

Amortization of software development costs 1,060 979

Non-cash stock compensation expense 618 1,034

Changes in operating assets and liabilities:

Accounts receivable (1,607) (52)

Computer hardware held for resale,

prepaid expenses, and other 904 854

Accounts payable and accrued expenses (630) 922

Deferred revenue including unearned

discount 778 993

Unrecognized tax benefits 50 46

Cash provided by operating activities 1,277 4,639

Investing activities

Purchases of property and equipment (492) (264)

Purchase of software - (2,300)

Purchases of held-to-maturity securities (189,410) (44,592)

Maturities of held-to-maturity securities 175,642 44,174

Purchases of available-for-sale securities (5,597) (13,587)

Sales of available-for-sale securities 37,919 15,240

Cash provided by (used in)

investing activities 18,062 (1,329)

Financing activities

Repurchases of common stock (21,703) -

Exercise of stock options 181 182

Cash (used in) provided by

financing activities (21,522) 182

Increase (decrease) in cash and cash

equivalents (2,183) 3,492

Cash and cash equivalents at beginning

of period 8,536 7,331

Cash and cash equivalents at end of period $6,353 $10,823

Supplemental disclosure of cash paid during

the period for:

Income taxes, net of refunds $115 $60

Non-cash investing activities:

Unrealized gain (loss) on

available-for-sale securities $11 $(29)

2008

Projected

Reconciliation of projected net loss to projected EBITDA

Projected net loss $(900)

Interest income 2,300

Operating loss (3,200)

Non-cash stock compensation expense 1,400

Depreciation and amortization 1,100

Amortization of software development costs 2,200

Projected pro-forma EBITDA $1,500

Reconciliation of net (loss)

income to EBITDA

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Net loss $(97) $(480) $(564) $(334)

Provision for income

taxes

(67) (26) (128) (88)

Interest income 572 930 1,361 1,887

Loss on sale of

investments - - (31) -

Operating loss (602) (1,384) (1,766) (2,133)

Non-cash stock

compensation expense 185 510 618 1,034

Depreciation and

amortization 277 264 552 538

Amortization of software

development costs 571 476 1,060 979

Pro-forma EBITDA $431 $(134) $464 $418

f net (loss) income determined under GAAP to pro-forma EBITDA is included below. Management believes that its pro- forma EBITDA measurement, when viewed in addition to the Company's reported GAAP results, provides an additional meaningful measure of operating performance, enabling investors to more thoroughly evaluate current performance in comparison to past performance. This information will necessarily differ from comparable information that may be provided by other companies and should not be considered in isolation or as an alternative to the Company's operating and other financial information determined under GAAP.

Cash and Cash Flow: AMICAS ended the second quarter of 2008 with a cash, cash equivalents, and marketable securities balance of $53.9 million, no long term debt, and working capital of $49.5 million. For the second quarter ended June 30, 2008, net cash provided by operations was $276,000.

Stock Repurchase: The Company repurchased approximately 6,586,000 shares of its common stock for approximately $17.1 million in the second quarter of 2008.

Fiscal Year-to-Date Financial Highlights

Revenue: Total revenues for the first six months of 2008 were $26.4 million, compared to $24.9 million for the first six months of 2007.

Operating Loss: Operating loss for the first six months of 2008 was $1.8 million, compared to an operating loss of $2.1 million for the first six months of 2007.

Net Loss: The Company's net loss for the first six months of 2008 was $564,000, or $(0.01) per share, compared to net loss of $334,000, or $(0.01) per share, for the first six months of 2007.

For the first six months of 2008, both operating loss and net loss included $618,000 of non-cash stock-based compensation expense and $1.6 million of depreciation and amortization. For the first six months of 2007, both operating loss and net loss included $1.0 million of non-cash stock-based compensation expense, and $1.5 million of depreciation and amortization.

Pro-forma EBITDA: For the first six months of 2008, pro-forma EBITDA was $464,000 as compared to $418,000 for the same period in 2007.

Cash Flow: For the first six months of 2008, net cash provided by operations was $1.3 million.

Stock Repurchase: During the fourth quarter of 2007, the Board of Directors directed the Company to initiate a $25 million stock repurchase plan. The Company repurchased approximately 6,586,000 shares of its common stock for approximately $17.1 million in the second quarter of 2008. The Company has repurchased approximately 8,568,000 shares for approximately $22.5 million in total under this program. Under a previously authorized stock repurchase plan, during 2006, the Company repurchased 4.5 million shares of its common stock for approximately $15.0 million, the total amount authorized by the Board of Directors under the prior plan.

Business Perspective

Dr. Stephen Kahane, president, chief executive officer, and chairman of AMICAS, said, "We had our best second quarter in the past several years. Bookings were solid and revenue growth was ahead of our plan. Once again, we maintained positive cash flow from operations while building our business through significant investments in both innovative research and development programs and important distribution initiatives. Similar to the last few quarters, the second quarter resulted in several large radiology groups making the decision to use AMICAS products as the basis for their automation infrastructure going forward. Over the past nine months, AMICAS has been able to sign several very sophisticated and informed radiology groups and imaging service providers. We will continue to work hard to help these new partners succeed and to make sure others follow in their footsteps. Our top-flight solutions, which include the latest in teleradiology technology, PACS, RIS, revenue cycle management, business intelligence, and zero client referring physician tools, continue to be viewed as extremely easy to install, deploy, and support. These attributes help reduce the total cost of ownership of AMICAS solutions, which can help result in very impressive returns on investment for our customers. As we have mentioned before, it is noteworthy that, despite obstacles such as DRA and other reimbursement-related pressures, these groups made the decision to take their automation support to the next level with industry leading offerings from AMICAS."

Dr. Kahane went on to say, "Our stock buyback program was very active in Q2, resulting in the purchase of over $17 million of AMICAS stock. The Company has repurchased approximately 8,568,000 shares for approximately $22.5 million in total under the $25 million program put in place in December of last year. Over the past two years, AMICAS has bought back over $37.5 million of its common stock. AMICAS has no debt and has a very strong recurring revenue base. We believe that our customers and the market recognize that AMICAS is committed to being the leading independent image and information management solutions provider in the healthcare industry. We believe that our innovative end-to-end suite of products, our strong and experienced team of professionals, and our dedicated focus on image and information management will help our customers and partners by empowering them to grow, differentiate, and efficiently run their practices and businesses in 2008 and beyond."

Dr. Kahane added, "We have entered the second half of 2008 energized, focused, and ready to work relentlessly to reach our goals and objectives and to become the leading independent vendor of choice in the image and information management marketplace."

Looking Forward

AMICAS continues to expect 2008 revenues to be between $52 million and $54 million. Pro-forma EBITDA is now expected to be approximately $1.5 million which is consistent with a net loss of approximately ($0.02) per share. AMICAS expects 2008 bookings growth of 10 to 20 percent. Bookings are defined as contractual commitments from customers for licenses, services, hardware, and maintenance/support.

Conference Call

AMICAS will host a conference call on Tuesday, August 5, at 8:30 a.m. Eastern Time to discuss the Company's 2008 second fiscal quarter results. Investors and other interested parties may dial in to the call using the toll free number 1.800.862.9098. (conference ID: 7AMICAS). The conference call will also be available via Webcast at http://www.amicas.com. Following the conclusion of the call, a replay will be available at 1.800.283.8183 or 402.220.0867 until September 4, 2008.

AMICAS, Vision Series, Vision Reach, RadStream and AMICAS Insight are trademarks or registered trademarks of AMICAS, Inc.

About AMICAS, Inc.

AMICAS, Inc. (http://www.amicas.com) is a leader in radiology and medical image and information management solutions. The AMICAS(R) Vision Series(TM) products provide a complete, end-to-end solution for imaging centers, ambulatory care facilities, and radiology practices. Acute care and hospital clients are provided a fully-integrated, HIS/RIS-independent PACS, featuring advanced enterprise workflow support and scalable design. Complementing the Vision Series product family is AMICAS Insight(TM) Solutions, a set of client-centered professional and consulting services that assist our customers with a well-planned transition to a digital enterprise. HIS and RIS mean hospital information system and radiology information system, respectively.

Safe Harbor Statement

Except for the historical information herein, the matters discussed in this release include forward-looking statements. In particular, the forward-looking statements contained in this release include statements about our anticipated financial and operating results for the remainder of fiscal year 2008. When used in this press release, the words: believes, intends, plans, anticipates, expects, estimates, and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause actual results to differ materially which include, but are not limited to, the following: a significant portion of the Company's quarterly sales are concluded in the last month of the fiscal quarter; the length of sales and delivery cycles; the deferral and/or realization of deferred software license and system revenues according to contract terms; the timing, cost and success or failure of current and new product and service introductions and product upgrade releases; potential patent infringement claims against AMICAS and the related defense costs; the ability of AMICAS to comply with all government laws, rules and regulations; and other risks affecting AMICAS' businesses generally and as set forth in AMICAS' most recent filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" of our most recent annual report on Form 10-K, and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this release are qualified by these cautionary statements and are made only as of the date of this release. AMICAS is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise. The financial statements and information as of, and for the period ended, June 30, 2008, contained in this press release are subject to review by the Company's independent registered public accounting firm.

CONTACT:

Colleen McCormick, Investor Relations

617-779-7892

cmccormick@amicas.com

Condensed Consolidated Balance Sheets

(Unaudited)

(in thousands, except share data)

June 30, December 31,

2008 2007

Assets

Current assets:

Cash and cash equivalents $6,353 $8,536

Marketable securities 47,527 67,071

Accounts receivable, net of allowances

of $290 and $231, respectively 11,980 10,483

Prepaid expenses and other current assets 2,700 3,600

Total current assets 68,560 89,690

Property and equipment, less accumulated

depreciation and Amortization of $7,178

and $6,848, respectively 1,334 1,186

Goodwill 27,313 27,313

Acquired/developed software, less

accumulated amortization of $9,052 and

$7,992, respectively 6,948 8,008

Other intangible assets, less accumulated

amortization of $1,956 and $1,742,

respectively 1,444 1,658

Other assets 1,583 586

Total Assets $ 107,182 $ 128,441

Liabilities and stockholders' equity

Current liabilities:

Accounts payable and accrued expenses $6,256 $7,094

Accrued employee compensation and benefits 1,658 1,451

Deferred revenue 11,153 10,375

Total current liabilities 19,067 18,920

Unrecognized tax benefits 1,326 1,275

Commitments and contingencies

Stockholders' equity:

Preferred stock $.001 par value; 2,000,000

shares authorized; none issued - -

Common stock $.001 par value, 200,000,000

shares authorized, 51,405,762 and 51,296,823

issued, respectively 51 51

Additional paid-in capital 229,855 229,056

Accumulated other comprehensive income 71 60

Accumulated deficit (99,042) (98,478)

Treasury stock, at cost, 15,207,435 and

6,824,192 shares (44,146) (22,443)

Total stockholders' equity 86,789 108,246

Total Liabilities and Stockholders' Equity $ 107,182 $ 128,441

Condensed Consolidated Statements Of Operations

(Unaudited)

(in thousands, except per share data)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Revenues

Maintenance and

services $10,552 $9,583 $20,305 $18,791

Software licenses and

system sales 3,023 2,919 6,058 6,144

Total revenues $13,575 $12,502 $26,363 $24,935

Costs and expenses

Cost of revenues:

Maintenance and

services (a) $4,692 $4,194 $8,961 $8,186

Software licenses and

system sales, including

amortization of software

costs of $571, $476,

$1,060 and $979,

respectively 1,731 1,670 3,942 3,189

Selling, general, and

administrative (b) 5,282 5,480 10,284 10,857

Research and

development ( c ) 2,195 2,278 4,390 4,300

Depreciation and

amortization 277 264 552 536

14,177 13,886 28,129 27,068

Operating loss (602) (1,384) (1,766) (2,133)

Interest income 572 930 1,361 1,887

Loss on sale of investments - - (31) -

Loss before provision

for income taxes (30) (454) (436) (246)

Provision for income taxes 67 26 128 88

Net loss $(97) $(480) $(564) $(334)

Loss per share

Basic: $(0.00) $(0.01) $(0.01) $(0.01)

Diluted: $(0.00) $(0.01) $(0.01) $(0.01)

Weighted average number

of shares outstanding

Basic 40,740 44,568 42,188 44,559

Diluted 40,740 44,568 42,188 44,559

(a) - includes $35,000, $27,000, $70,000, and $48,000 in stock-based

compensation expense for the three and six months ended June 30,

2008, and June 30, 2007, respectively.

(b) - includes $50,000, $0.4 million, $0.3 million, and $0.9 million in

stock-based compensation expense for the three and six months

ended June 30, 2008, and June 30, 2007, respectively.

( c ) - includes $100,000, $71,000, $213,000, and $133,000 in stock-based

compensation expense for the three and six months ended June 30,

2008, and June 30, 2007, respectively.


'/>"/>

SOURCE AMICAS, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arcadia Radiology Medical Group Chooses AMICAS
2. AMICAS Announces Integrations at More Than 100 MEDITECH Facilities
3. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
4. AMICAS to Present at CIBC World Markets 18th Annual Healthcare Conference
5. eResearchTechnology Reports Second Quarter 2008 Results
6. SuperGen Reports 2008 Second Quarter Financial Results
7. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
8. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
9. CV Therapeutics Reports 2008 Second Quarter Financial Results
10. Gentiva Reports Strong Second Quarter led by Home Health Segment
11. United Therapeutics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
(Date:6/23/2016)... , June 23, 2016 ... market research report to its pharmaceuticals section with ... product details and much more. Complete ... across 151 pages, profiling 15 companies and supported ... at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The ...
Breaking Biology Technology:
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
Breaking Biology News(10 mins):